Skip to content

Price / book at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
9.1×-17.0×
Revvity logo
RevvityRVTY
1.4×-0.3×
Roivant Sciences logo
Roivant SciencesROIV
4.4×+2.8×
Incyte logo
IncyteINCY
3.3×+0.1×
Gilead Sciences logo
Gilead SciencesGILD
7.4×+0.1×
AbbVie logo
AbbVieABBV
261×+221×

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Calculated from Krystal Biotech, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s price / book?
Krystal Biotech, Inc. (KRYS) reported price / book of 5.9× in Q1 2026.
How has Krystal Biotech, Inc.'s price / book changed year-over-year?
Krystal Biotech, Inc.'s price / book increased by 12.1% year-over-year, from 5.3× to 5.9×.
What is the long-term trend for Krystal Biotech, Inc.'s price / book?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s price / book has grown at a 2.8% compound annual growth rate (CAGR), from 5.1× to 5.9×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.